Piper Sandler raised the firm’s price target on Cardiff Oncology to $7 from $5 and keeps an Overweight rating on the shares. Cardiff reported strong FY23 earnings and disclosed data from the now discontinued randomized Phase II 2L RAS colorectal cancer trial, the analyst tells investors in a research note. The firm thinks the data have provided a some de-risking for onvansertib within CRC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRDF:
- Cardiff Oncology Reports Progress in Colorectal Cancer Trials
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- CRDF Earnings this Week: How Will it Perform?
